Zhuang Qunchuan, Shen Aling, Liu Liya, Wu Meizhu, Shen Zhiqing, Liu Huixin, Cheng Ying, Lin Xiaoying, Wu Xiangyan, Lin Wei, Li Jiapeng, Han Yuying, Chen Xiaoping, Chen Qi, Peng Jun
Biomedical Research Center of South China, Fujian Normal University, Fuzhou, Fujian 350117, P.R. China.
Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China.
Oncol Lett. 2021 Jul;22(1):526. doi: 10.3892/ol.2021.12787. Epub 2021 May 13.
Valuable diagnostic and prognostic biomarkers are urgently needed for colorectal cancer (CRC), which is one of the leading causes of mortality worldwide. Previous studies have reported altered expression of a mucin-like protein Fc fragment of IgG binding protein (FCGBP) in various types of cancer, but its potential diagnostic, prognostic and immunological roles in CRC remain to be determined. Therefore, the aim of current study was to investigate the potential roles of FCGBP in CRC. The present study investigated FCGBP mutations and changes in its expression levels using a combination of microarray and public dataset analyses, as well as immunohistochemistry. The results demonstrated a 10.5% mutation frequency in the coding sequence in CRC tissues, and identified decreased FCGBP mRNA or protein expression levels in colorectal adenoma and CRC (compared with those in normal colorectal tissues from healthy control subjects), including pathologically advanced CRC (stage III+IV vs. I+II). Survival analysis using the GEPIA and Kaplan-Meier Plotter databases revealed that low FCGBP expression levels were associated with short overall, disease-free, relapse-free and event-free survival times in patients with CRC. Notably, analysis using the online Tumor IMmune Estimation Resource database revealed a positive correlation between expression levels and the extent of infiltrating immune cells, such as B cells and dendritic cells. Consistently, the expression levels of most markers (51/57) for various types of immune cells were significantly correlated with expression levels in CRC tissues. These findings suggested that FCGBP may serve as a diagnostic and prognostic biomarker, and that FCGBP may be associated with immune infiltration in CRC.
结直肠癌（CRC）是全球主要死因之一，迫切需要有价值的诊断和预后生物标志物。先前的研究报道了黏蛋白样蛋白IgG结合蛋白Fc片段（FCGBP）在各种癌症中的表达改变，但其在结直肠癌中的潜在诊断、预后和免疫作用仍有待确定。因此，本研究的目的是探讨FCGBP在结直肠癌中的潜在作用。本研究结合微阵列和公共数据集分析以及免疫组织化学，研究了FCGBP突变及其表达水平的变化。结果显示，结直肠癌组织编码序列中的突变频率为10.5%，并确定结直肠腺瘤和结直肠癌中FCGBP mRNA或蛋白表达水平降低（与健康对照受试者的正常结直肠组织相比），包括病理分期较晚的结直肠癌（III+IV期 vs. I+II期）。使用GEPIA和Kaplan-Meier Plotter数据库进行的生存分析显示，FCGBP低表达水平与结直肠癌患者较短的总生存期、无病生存期、无复发生存期和无事件生存期相关。值得注意的是，使用在线肿瘤免疫评估资源数据库进行的分析显示，表达水平与浸润免疫细胞（如B细胞和树突状细胞）的程度呈正相关。同样，各种免疫细胞的大多数标志物（51/57）的表达水平与结直肠癌组织中的表达水平显著相关。这些发现表明，FCGBP可能作为一种诊断和预后生物标志物，并且FCGBP可能与结直肠癌中的免疫浸润有关。
